Clinical Trial Update: A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC) [Phase 3]

View source ↗

Summary

This clinical trial update covers a Phase 3 study evaluating TAR-200 with or without cetrelimab versus intravesical BCG in patients with high-risk non-muscle in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-muscle Invasive Bladder Cancer

Drugs mentioned

• Bacillus Calmette-Guérin (Bacillus Calmette-Guérin)
• Cetrelimab
• TAR-200

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Bladder Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING